ADCs [14,15], such as sacituzumab govitecan (Trodelvy®), selectively deliver cytotoxic agents to cancer cells while minimizing damage to healthy cells, and targeted therapies based on specific molecular mechanisms [16], like phosphoinositide 3-kinase (PI3K) inhibitors, e.g., alpelisib, buparlisib, and mammalian target of rapamycin (mTOR) inhibitors, e.g., everolimus, offer new avenues for TNBC treatment. This evidence concerns the gene MTOR and cancer.